ABSTRACT
Cholangiocarcinoma (CCA) is a malignant disease of the biliary tree which accounts for 15% of primary liver cancers and 3% of gastrointestinal malignancies. For almost a decade, palliative chemotherapy remained the standard of care for advanced CCA with only modest disease control and survival rates, both in first- and second-line settings. In recent years, thanks to the advances of next-generation sequencing (NGS), an extensive range of targetable genetic alterations has been identified. In this review, we highlight different driver genomic alterations and their relative frequencies in advanced CCA, and we provide an updated overview of the current targeted treatment landscape.

IMPACT STATEMENT 
This review highlights different driver molecular alterations and their relative frequencies in advanced CCA and provides an updated overview of the current targeted treatment landscape.

Full text below.